Q1 2025 Nolato AB Earnings Call Transcript
Key Points
- Nolato AB (FRA:NBF) reported a strong increase in margins, reaching 11%, with an EBITA of SEK271 million.
- The Medical Solutions segment, which accounts for 57% of total sales, showed significant margin improvement, increasing by 1.9 percentage points to 12.2%.
- The company maintains a strong financial position with net financial liabilities at 0.5 times adjusted operating profit, enabling further expansion and acquisitions.
- The Materials business within Engineered Solutions experienced a robust growth of 12% in the quarter.
- Nolato AB (FRA:NBF) successfully acquired a property in Poland for future expansion, indicating strategic growth plans in Europe.
- Sales in the Engineered Solutions segment were slightly lower due to a decline in the automotive sector.
- The IVD (In Vitro Diagnostics) segment experienced lower volumes, attributed to quarterly volatility.
- Higher working capital requirements negatively impacted cash flow from operating activities.
- Net investments increased to SEK271 million, up from SEK230 million the previous year, due to significant CapEx in Hungary and property acquisition in Poland.
- The US operations within the Medical segment, while improving, still have margins below the business area average.
Hello, and welcome to today's presentation with Nolato. With us presenting today, we have the CEO, Christer Wahlquist; and CFO, Per-Ola Holmstrom. (Operator Instructions) And with that said, please go ahead with your presentation.
Thank you, and welcome to the presentation of Nolato's first-quarter 2025. This is Christer Wahlquist speaking. If we summarize the quarter, we had similar sales as comparison quarter, but with a very strong increase of our margins amounting to 11% as a total, creating an EBITA on SEK271 million. We saw growth within the Medical, but slightly lower sales for Engineered Solutions due to the automotive sector. If we look on the margins, we strengthened the margins in both business areas, but particularly strong performance for Medical Solutions.
Still, we have a very strong financial position with net financial liabilities in relation to adjusted operating profit of 0.5 times. Moving to page 3 in the presentation deck. Looking at the two parts of our business:
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
